|
|
' i4 K% r: b! V: B9 F( E3 B, QVaccines, 6th Edition 2 s$ G9 U8 [% M/ j, F8 O3 b
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.
- H" @5 G/ |8 t5 A- Z: E* [& {2 t. T
9 j5 X! e! v7 P( q5 [4 E1 whttp://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606
& Q5 n/ G+ n# ^9 d- R7 O1 f) A" {# P- P% e/ h$ ~! N5 ?2 }# D
SECTION 1: General aspects of vaccination
$ c8 D2 s( z; u1 A short history of vaccination 1( J/ w4 z4 \+ n
2 Vaccine immunology 14' R$ F0 C, n3 g- j0 P- t( h
3 The vaccine industry 33
1 U2 P' T* Z* M! z# ~# y8 K; @8 @4 Vaccine manufacturing 44
9 Y( N* j4 R8 U6 X" q5 Evolution of adjuvants across the centuries 58- B. K+ U& g" j8 Z
6 Vaccine additives and manufacturing residuals in the United States:
8 N: M; E) \3 ^6 I/ }3 f; o9 ?/ ]licensed vaccines 71
& m7 \/ r' Q/ L7 Passive immunization 80
, ?- c, _$ W; e* @8 General immunization practices 88- _+ n+ ]: Z7 z9 D8 `
SECTION 2: Licensed vaccines) d( P6 B+ [/ ]" p6 S- c
9 Adenovirus vaccines 113
. c6 ?1 r# }# D/ j5 j10 Anthrax vaccines 127
7 X3 l; s4 b, i7 c0 N11 Cholera vaccines 141
5 K N7 s6 w) R, L. p; H12 Diphtheria toxoid 153
9 V! I+ K0 K) S+ G" l! g z13 Haemophilus influenzae vaccines 167
. T# E" ~/ _- u& c" g14 Hepatitis A vaccines 183
0 e6 p. r* _, S3 O0 k& i( X15 Hepatitis B vaccines 205
" c+ D8 @; y. d# {7 I* c16 Human papillomavirus vaccines 235
# I: u2 n- W/ H' ^7 i! o. g9 @17 Inactivated influenza vaccines 257& D( G$ i# {* v2 f! Q1 p
18 Influenza vaccine-live 2947 f4 m! L, P4 v: ~4 V+ W
19 Japanese encephalitis vaccines 312, X/ A5 o1 _8 A% V! a0 t7 q
20 Measles vaccines 352
& R2 T2 b/ R$ U21 Meningococcal vaccines 388$ U! P0 P' i! U' x4 I4 g/ R% C
22 Mumps vaccine 4191 F- K6 d1 h! H9 ?8 d5 G6 E* |) s
23 Pertussis vaccines . 4472 }# T7 C, e6 T" D8 |0 _2 x
24 Plague vaccines 493
: b" ] D; p4 c' U E25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
* c$ z5 c7 z8 L2 Q: Y x; B1 v1 t26 Pneumococcal polysaccharide vaccines 542' r. ?, D: w) e3 O" [( p, `- k
27 Poliovirus vaccine-inactivated . 573
# z$ T% M' z+ }1 z/ j3 c2 p28 Poliovirus vaccine-live 5980 [! V5 ], P' G
29 Rabies vaccines .6460 [; c- v `: V# B7 }3 e. Y
30 Rotavirus vaccines . 669
+ p1 ^! v& C; u, l31 Rubella vaccine 688
; r# a" G: x4 h% M9 P& M4 Z7 M32 Smallpox and vaccinia 718
s" v) u& j; j33 Tetanus toxoid 746! J; ~, j- ^- |) M+ r
34 Tick-borne encephalitis virus vaccines 7732 p9 K& X" @9 j% P' ^ D! U3 a
35 Tuberculosis vaccines 789
9 C; Z8 z( N, F* G3 l36 Typhoid fever vaccines 812- g% Q2 z$ E, g2 x8 ]! L
37 Varicella vaccine 837
9 { Y4 q+ u" B1 E38 Yellow fever vaccine 870" |! L% Y* D& q$ C
39 Zoster vaccine 969, e1 x" }" ~" b8 P
40 Combination vaccines 981
0 e, ^3 N2 G+ S, |/ ~6 n. rSECTION 3: Vaccines in development and new vaccine strategies
2 R) P# ~5 O; P7 e, B Q6 Q41 Biodefense and special pathogen vaccines 10085 `7 {' Z& S y. ~9 n
42 Therapeutic cancer vaccines 1018" C. w4 O; U, P! N2 p% x+ U
43 Cytomegalovirus vaccines 1032
0 y: ~) U2 m5 I5 t2 K) c44 Dengue vaccines 10425 m% n0 N. e- l! u
45 Diarrhea caused by bacteria 1052! V/ w) R- j# ^/ f: P @
46 Ebola vaccine 1060) r. D& A* q# K2 m/ m
47 Epstein-Barr virus vaccines 1068
& A3 k# H/ ]) t R) M* @1 B48 Hepatitis C vaccines 1074
% H# }" y7 i1 h) I% c: n+ ?49 Hepatitis E vaccines 1085/ G& v3 i8 q; g, D+ ^
50 Herpes simplex virus vaccines 10902 _$ o6 y4 j* U
51 Human immunodeficiency virus vaccines 1097* S$ G; w5 T/ D* X% l
52 Lyme disease vaccines 1122+ b1 ~1 _8 Y% s% M
53 Malaria vaccines 1133
6 i0 Q/ v! x T- z54 Noninfectious disease vaccines 11381 s- l6 n+ k3 |2 f
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
/ W. y; l2 Y5 ]- ?56 Parasitic disease vaccines 1154+ H2 R+ x5 S- N" i: i9 o
57 Staphylococcus aureus vaccines 1161
( m) j+ X, A6 _' c1 }, [58 Streptococcus group A vaccines 1169
- o( z# }: V$ A0 \& J59 Streptococcus group B vaccines 1176( a' H, @1 V4 j0 b( {
60 Technologies for making new vaccines 1182
, G" m) K1 O) N0 g S61 Alternative vaccine delivery methods 1200
: \& X+ W% @: t4 L62 The development of gene-based vectors for immunization 12320 J0 O0 s1 j) \8 z# F
SECTION 4: Vaccination of special groups4 ] H1 n; f+ y0 B
63 Vaccination of immunocompromised hosts 1243! \0 S3 J6 l- d) n0 a" |
64 Vaccination of human immunodeficiency virus-infected persons 1257) K/ T0 N$ i' |1 Q- g
65 Vaccines for international travel 1270) f: d& ~. [# Y7 [9 b" C0 N
66 Vaccines for health care personnel 1290
2 N# T+ P2 r" p; l! SSECTION 5: Public health and regulatory issues
6 v( p4 k- p. q: `% v& N4 k/ h67 Immunization in the United States 1310# D0 m- h: {, L6 N4 z$ m" s
68 Immunization in Europe . 13345 N) u3 x V, \: X- a
69 Immunization in the Asia-Pacific region 13534 P8 s0 S6 l: d- W& c+ H+ b( T
70 Immunization in developing countries 13694 B: @0 ]8 X* X, \/ e6 n/ q
71 Community immunity 1395
$ c/ w+ Y7 Z1 m2 ^! G: }1 J, W72 Economic analyses of vaccine policies 14132 U% `2 K# T& Q1 }
73 Regulation and testing of vaccines 1427
8 |3 I& A7 n. r9 ^74 Regulation of vaccines in Europe 1447
4 f* N$ |% w9 ]& Q75 Regulation of vaccines in developing countries 14544 t+ ]$ ?, i, y) S) @' t
76 Vaccine safety 1464" \( P! ~; w1 W" q- k( {6 q" I! M& P
77 Legal issues . 1481, D2 Q0 e1 i6 b! Y
78 Ethics 1508( `- D3 }8 l: ?+ Q4 h
: \' {2 v1 M5 N x/ u
; h! }& |7 o& q
9 d* ^$ ~8 \, l4 `8 p7 b, [$ \7 Q1 D- t- |( T) J2 c
|
|
发表于 2015-7-25 14:07:34
发表于 2015-7-26 14:55:58
' s5 ]5 M+ f8 J) ^) x5 A4 L